India’s Pharma Market: How Exports and R&D Are Fueling a USD 50 Billion Industry

The Indian pharmaceutical market for FY 2023-24 is valued at USD 50 billion, with domestic consumption contributing USD 23.5 billion and exports at USD 26.5 billion. India stands as the third-largest by volume and 14th by value globally, driven by a diverse product base including generics, biologics, and vaccines. As per the National Accounts Statistics 2024, the pharmaceutical sector’s total output was ₹4,56,246 crores in FY 2022-23, employing over 9 lakh individuals.

Research and Development Initiatives

India has prioritised R&D through institutions like the National Institutes of Pharmaceutical Education & Research (NIPERs), which focus on postgraduate education and advanced research. The National Policy on R&D and Innovation in Pharma-MedTech Sector, introduced in August 2023, aims to foster innovation and drug discovery through:

• Regulatory frameworks supporting safety and quality.
• Fiscal incentives for public and private investments.
• Building an enabling ecosystem for cross-sectoral innovation.

PRIP Scheme: Strengthening Pharma Innovation

The Promotion of Research & Innovation in Pharma Sector (PRIP) scheme, with a ₹5000 crore outlay for five years, focuses on:

1. Establishing Centres of Excellence in NIPERs.
2. Funding in-house and academic R&D in priority areas.

Streamlined Clinical Trials Rules

The New Drugs and Clinical Trials Rules 2019 introduced key measures to expedite drug approvals and encourage innovation:

• Faster approvals within 90 days.
• Automatic approvals if timelines are exceeded.
• Accelerated processes for orphan drugs and unmet medical needs.

Intellectual Property Enhancements

To strengthen the IP regime, initiatives like:

• Amendments in patent rules for expedited processes.
• Rebates for start-ups and educational institutions.
• Extension of the Start-Ups Intellectual Property Protection (SIPP) scheme to 2026 with increased facilitation fees.

India’s Export Success

India’s exports, valued at USD 26.5 billion, underscore its position as a global pharma leader. Compliance with importing country regulations ensures product quality and competitiveness.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.